Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1358894 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design) and Effect of Food on the Relative Bioavailability of BI 1358894 (Open-label, Randomised, Two-way Cross-over)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
At a glance
- Drugs BI 1358894 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 31 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 29 Oct 2018 Planned End Date changed from 26 Nov 2018 to 6 Feb 2019.
- 29 Oct 2018 Planned primary completion date changed from 26 Nov 2018 to 6 Feb 2019.